News, features, and commentary about cancer-related issues ...

New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants published by Wiley online in CANCER, investigators found ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Read more about the under-prescription of first-line treatments for erectile dysfunction in patients with prostate cancer.

No increased risk for thrombosis or bleeding seen with concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs.

By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ...